Get the Stockscreener App
2.03
5.18%
0.10
After Hours:
2.07
0.04
+1.97%
Serina Therapeutics Inc stock is traded at $2.03, with a volume of 80,943.
It is up +5.18% in the last 24 hours and up +30.97% over the past month.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.
See More
Previous Close:
$1.93
Open:
$1.93
24h Volume:
80,943
Relative Volume:
0.02
Market Cap:
$25.00M
Revenue:
$130.00K
Net Income/Loss:
$-19.22M
P/E Ratio:
-1.0715
EPS:
-1.8946
Net Cash Flow:
$-18.01M
1W Performance:
+0.50%
1M Performance:
+30.97%
6M Performance:
-60.58%
1Y Performance:
-60.20%
1-Day Range:
$1.92
$2.07
1-Week Range:
$1.85
$2.30
52-Week Range:
$1.22
$7.92
Serina Therapeutics Inc Stock (SER) Company Profile
Name
Serina Therapeutics Inc
Sector
Industry
Phone
(256) 327-9630
Address
601 GENOME WAY, HUNTSVILLE
Compare SER vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SER
Serina Therapeutics Inc
|
2.03 | 23.77M | 130.00K | -19.22M | -18.01M | -1.8946 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Serina Therapeutics Inc Stock (SER) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-14-25 | Initiated | H.C. Wainwright | Buy |
Serina Therapeutics Inc Stock (SER) Latest News
Serina Therapeutics (SER) stock surges over 39% after hours—here's why - MSN
Market Review: What is the dividend yield of Serina Therapeutics IncWeekly Trend Recap & Verified Momentum Stock Alerts - baoquankhu1.vn
Take Profit: What is the dividend yield of Serina Therapeutics IncMarket Growth Report & Free High Return Stock Watch Alerts - baoquankhu1.vn
Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit - Sahm
Serina Therapeutics, Inc Announces Novel Lipid Nanoparticles Built On POZ Platform - marketscreener.com
Recap Report: Will PHUN be affected by tariffs2026 PreEarnings & Risk Controlled Swing Alerts - baoquankhu1.vn
Serina says its nanoparticle polymer avoided antibodies in rat study - Stock Titan
Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan - Sahm
Serina Therapeutics wins NYSE approval; 2027 listing compliance deadline set - MSN
Serina Therapeutics announces NYSE American acceptance of continued listing compliance plan - marketscreener.com
Serina Therapeutics Announces NYSE American Acceptance Of Continued Listing Compliance Plan - TradingView
SER Technical Analysis & Stock Price Forecast - Intellectia AI
Stock List: Research Stocks from Around the World - GuruFocus
Serina Therapeutics (SER) files 10-K amendment to correct auditor consent - stocktitan.net
New funding to support Serina’s SER-252 trial in advanced Parkinson’s - Parkinson's News Today
SER Stock Price and Chart — AMEX:SER - TradingView
Serina Therapeutics POZ Drug Delivery Platform: Technology Overview, Pipeline, and Intellectual Property Portfolio - Minichart
Serina Therapeutics' 2025 net loss widens as R&D expenses jump - TradingView
Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights - marketscreener.com
Serina Therapeutics (NYSE: SER) posts 2025 loss while funding SER-252 trials - Stock Titan
[10-K] Serina Therapeutics, Inc. Fi... - Stock Titan
Serina Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Parkinson's drug candidate reaches patients as Serina lines up $30M - Stock Titan
Top Executive Makes Notable Move With Serina Therapeutics Stock - TipRanks
Serina Therapeutics CSO Moreadith sells $18,567 in stock - Investing.com
Serina Therapeutics CSO Moreadith sells $18,567 in stock By Investing.com - Investing.com Canada
Serina Therapeutics (SER) CSO exercises options then sells 6,500 shares - Stock Titan
Serina Therapeutics Raises Up to $30 Million to Advance SER-252 Parkinson’s Drug Trial and Secures Additional Funding Opportunities - Minichart
Serina Therapeutics to Present at 38th Annual Roth Conference - National Today
Serina Therapeutics to Present at the 38th Annual Roth Conference - Bitget
Serina Therapeutics Inc appoints Greg Bailey as co-chairman of boardSEC filing - MarketScreener
Serina Therapeutics IncAppoints Greg Bailey As Co-Chairman Of BoardSEC Filing - TradingView — Track All Markets
Serina Therapeutics (SER) lines up $30M private placement plus $33.3M warrant upside - Stock Titan
Serina Therapeutics Inc. Faces Stock Volatility Amid Economic Challenges - StocksToTrade
Risk Check: What is the dividend yield of Serina Therapeutics IncEarnings Recap Summary & Daily Profit Focused Stock Screening - baoquankhu1.vn
Serina Therapeutics secures up to $30M in private placement - MSN
Serina Therapeutics Insider Sells $97,500 in Stock - National Today
Top Serina Therapeutics Executive Makes Notable Stock Move - TipRanks
Serina Therapeutics CSO sells $97,500 in shares By Investing.com - Investing.com Canada
Serina Therapeutics (SER) CSO exercises options and sells 39,000 shares - Stock Titan
Serina Therapeutics Inc. Rallies on Dynamic Market Expansion Prospects - timothysykes.com
Serina Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | 2BO | US81751A1088 - marketscreener.com
Stock Market Today: Futures Drop Ahead Of 'Triple Witching' Session As Iran Threatens 'Zero Restraint'— FedEx, Super Micro In Focus (UPDATED) - Benzinga
Serina Therapeutics (SER) Stock Jumps 39% Following $63M Financing Deal and Leadership Announcement - MEXC
Serina Therapeutics (SER) Stock Climbs 39% on Private Placement and Greg Bailey Appointment - MEXC
Biotech Microcap Rockets After Securing Major Capital Infusion at Premium Valuation - The Globe and Mail
SER Stock Surges Amid Strategic Acquisitions and Partnerships - StocksToTrade
Serina Therapeutics (SER) Stock Soars 39% After Announcing $63M Funding and Leadership Boost - parameter.io
Serina Therapeutics (SER) Stock Soars 39% After $30M Funding Deal and Leadership Boost - MoneyCheck
Serina Therapeutics’ Stock Hits All-Time Low Amid Financial Challenges - timothysykes.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Serina Therapeutics Inc Stock (SER) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Cap:
|
Volume (24h):